NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
NervGen announced positive independent, blinded biomechanical gait analyses for its lead asset NVG-291 in the Phase 1b/2a CONNECT SCI study. The Global Statistical Test showed a significant treatment effect favoring NVG-291 (p=0.0197), with 100% of treated subjects classified as responders versus 10% of placebo subjects (p=0.0001).
Key figures
- Drug Name
- NVG-291
- Phase Of Trial
- Phase 1b/2a
- P value gte
- 0.0197
- P value responder
- 0.0001
- Coordination p value
- 0.007
- Nv G291 responder rate
- 100%
- Placebo responder rate
- 10%
- Global treatment effect
- +0.45
- Mechanical effort p value
- 0.038
- Postural stability p value
- 0.044
- Probability of treatment benefit
- 72.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.